Dr. Lorne Tyrrell,
holds the CIHR/GSK Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. He has focused his research since 1986 on viral hepatitis. His work on the development of antiviral therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 200 countries worldwide for the treatment of HBV. He has also been involved in the establishment of two biotech companies – KMT Hepatech (a private company) and ViRexx (a publicly-traded company).
12:00 pm – 1:00 pm, 2104 Dentistry Pharmacy

“Lessons From The Past And Future Directions For Alberta’s Biotech Industry”

The Technology Commercialization group at the University of Alberta is proud to present the first of a series of lectures featuring scientists who have succeeded in bringing science and business together.